The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Targeting the phosphoinositide 3-kinase pathway in cancer
Open accessAbstract
The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer. This pathway therefore presents both an opportunity and a challenge for cancer therapy. Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clinical trials, major issues remain. Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pedrero, J. M. G., Carracedo, D. G., Pinto, C. M., Zapatero, A. H., Rodrigo, J. P., Nieto, C. S., & Gonzalez, M. V. (2005) · International Journal of Cancer · doi:10.1002/ijc.20711 · Cited by 235
RetractedComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,006
Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., & Birnbaum, M. J. (2001) · Science · doi:10.1126/science.292.5522.1728 · Cited by 1,836
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
The PI3K‒PDK1 connection: more than just a road to PKB
Vanhaesebroeck, B., & Alessi, D. R. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3460561 · Cited by 1,644
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Pten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516
Aguirre, V., Uchida, T., Yenush, L., Davis, R., & White, M. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.9047 · Cited by 1,487
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Fruman, D. A., Meyers, R. E., & Cantley, L. C. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.481 · Cited by 1,355
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Central Role for G Protein-Coupled Phosphoinositide 3-Kinase γ in Inflammation
Hirsch, E., Katanaev, V. L., Garlanda, C., Azzolino, O., Pirola, L., Silengo, L., Sozzani, S., Mantovani, A., Altruda, F., & Wymann, M. P. (2000) · Science · doi:10.1126/science.287.5455.1049 · Cited by 1,209
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,190
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G. F., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., McCormick, F., Tempst, P., et al. (1998) · Science · doi:10.1126/science.279.5351.710 · Cited by 1,059
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Yang, H., Kong, W., He, L., Zhao, J.-J., O'Donnell, J. D., Wang, J., Wenham, R. M., Coppola, D., Kruk, P. A., Nicosia, S. V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2488 · Cited by 1,051
Self-citationTenets of PTEN Tumor Suppression
Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,034
Function of PI3Kγ in Thymocyte Development, T Cell Activation, and Neutrophil Migration
Sasaki, T., Irie-Sasaki, J., Jones, R. G., Oliveira-dos-Santos, A. J., Stanford, W. L., Bolon, B., Wakeham, A., Itie, A., Bouchard, D., Kozieradzki, I., et al. (2000) · Science · doi:10.1126/science.287.5455.1040 · Cited by 1,031
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
Stallone, G., Schena, A., Infante, B., Di Paolo, S., Loverre, A., Maggio, G., Ranieri, E., Gesualdo, L., Schena, F. P., & Grandaliano, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042831 · Cited by 990
High-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., DeBiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 988
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., et al. (2002) · Science · doi:10.1126/science.1073560 · Cited by 946
Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 921
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
The Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 821
Roles of PLC-β2 and -β3 and PI3Kγ in Chemoattractant-Mediated Signal Transduction
Li, Z., Jiang, H., Xie, W., Zhang, Z., Smrcka, A. V., & Wu, D. (2000) · Science · doi:10.1126/science.287.5455.1046 · Cited by 807
Oncogenic PI3K deregulates transcription and translation
Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1753 · Cited by 798
Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Alessi, D. R., Deak, M., Casamayor, A., Barry Caudwell, F., Morrice, N., Norman, D. G., Gaffney, P., Reese, C. B., MacDougall, C. N., Harbison, D., et al. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00336-8 · Cited by 737
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J. G., Jen, J., Isaacs, W. B., Bova, G. S., & Sidransky, D. (1997) · PubMed · Cited by 700
Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 688
Self-citationThe regulation and function of Class III PI3Ks: novel roles for Vps34
Backer, J. M. (2008) · Biochemical Journal · doi:10.1042/bj20071427 · Cited by 659
Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630
PKB/AKT: functional insights from genetic models
Scheid, M. P., & Woodgett, J. R. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096067 · Cited by 609
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
PI 3-kinase p110β: a new target for antithrombotic therapy
Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide, S. M., Yuan, Y., et al. (2005) · Nature Medicine · doi:10.1038/nm1232 · Cited by 580
Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways
Crackower, M. A., Oudit, G. Y., Kozieradzki, I., Sarao, R., Sun, H., Sasaki, T., Hirsch, E., Suzuki, A., Shioi, T., Irie-Sasaki, J., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00969-8 · Cited by 576
Self-citationThe Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations
Huang, C.-H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 560
Targeting phosphoinositide 3-kinase—Moving towards therapy
Marone, R., Cmiljanovic, V., Giese, B., & Wymann, M. P. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.10.003 · Cited by 548
PTEN-deficient cancers depend on PIK3CB
Wee, S., Wiederschain, D., Maira, S.-M., Loo, A., Miller, C., deBeaumont, R., Stegmeier, F., Yao, Y.-M., & Lengauer, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802655105 · Cited by 545
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543
WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
Graupera, M., Guillermet-Guibert, J., Foukas, L. C., Phng, L.-K., Cain, R. J., Salpekar, A., Pearce, W., Meek, S., Millan, J., Cutillas, P. R., et al. (2008) · Nature · doi:10.1038/nature06892 · Cited by 520
Impaired B Cell Development and Proliferation in Absence of Phosphoinositide 3-Kinase p85α
Fruman, D. A., Snapper, S. B., Yballe, C. M., Davidson, L., Yu, J. Y., Alt, F. W., & Cantley, L. C. (1999) · Science · doi:10.1126/science.283.5400.393 · Cited by 516
(1997) · PubMed · Cited by 512
Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 509
Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse
Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., & P Pandolfi, P. (2001) · Nature Genetics · doi:10.1038/84879 · Cited by 498
Engelman, J. A., Jänne, P. A., Mermel, C., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 493
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
Garcia-Echeverria, C., & Sellers, W. R. (2008) · Oncogene · doi:10.1038/onc.2008.246 · Cited by 473
Patrucco, E., Notte, A., Barberis, L., Selvetella, G., Maffei, A., Brancaccio, M., Marengo, S., Russo, G., Azzolino, O., Rybalkin, S. D., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.017 · Cited by 468
Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation
Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J. H., Withers, D. J., & Vanhaesebroeck, B. (2006) · Nature · doi:10.1038/nature04694 · Cited by 463
Xid -Like Immunodeficiency in Mice with Disruption of the p85α Subunit of Phosphoinositide 3-Kinase
Suzuki, H., Terauchi, Y., Fujiwara, M., Aizawa, S., Yazaki, Y., Kadowaki, T., & Koyasu, S. (1999) · Science · doi:10.1126/science.283.5400.390 · Cited by 459
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
Philp, A., Campbell, I., Leet, C. S. F., Vincan, E., Rockman, S., Whitehead, R. H., Thomas, R. J., & Phillips, W. A. (2001) · PubMed · Cited by 455
Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A., & Nussbaum, R. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10963 · Cited by 452
Clayton, E., Bardi, G., Bell, S. E., Chantry, D., Downes, C. P., Gray, A., Humphries, L. A., Rawlings, D., Reynolds, H., Vigorito, E., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020805 · Cited by 446
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., & Knight, Z. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.117 · Cited by 440
c-Jun N-terminal Kinase (JNK) Mediates Feedback Inhibition of the Insulin Signaling Cascade
Lee, Y. H., Giraud, J., Davis, R. J., & White, M. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208359200 · Cited by 438
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 438
PIK3CA as an oncogene in cervical cancer
Ma, Y.-Y., Wei, S.-J., Lin, Y.-C., Lung, J.-C., Chang, T.-C., Whang-Peng, J., Liu, J. M., Yang, D.-M., Yang, W. K., & Shen, C.-Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203597 · Cited by 434
Hunter, C., Smith, R., Cahill, D. P., Stephens, P., Stevens, C., Teague, J., Greenman, C., Edkins, S., Bignell, G., Davies, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0127 · Cited by 434
Cancer-specific mutations in PIK3CA are oncogenic in vivo
Bader, A. G., Kang, S., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510857103 · Cited by 420
Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit
Miled, N., Yan, Y., Hon, W.-C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H. J., Backer, J. M., & Williams, R. L. (2007) · Science · doi:10.1126/science.1135394 · Cited by 410
Terauchi, Y., Tsuji, Y., Satoh, S., Minoura, H., Murakami, K., Okuno, A., Inukai, K., Asano, T., Kaburagi, Y., Ueki, K., et al. (1999) · Nature Genetics · doi:10.1038/6023 · Cited by 399
Essential role for the p110δ phosphoinositide 3-kinase in the allergic response
Ali, K., Bilancio, A., Thomas, M., Pearce, W., Gilfillan, A. M., Tkaczyk, C., Kuehn, N., Gray, A., Giddings, J., Peskett, E., et al. (2004) · Nature · doi:10.1038/nature02991 · Cited by 387
PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR
Bernardi, R., Guernah, I., Jin, D., Grisendi, S., Alimonti, A., Teruya-Feldstein, J., Cordon-Cardo, C., Celeste Simon, M., Rafii, S., & Pandolfi, P. P. (2006) · Nature · doi:10.1038/nature05029 · Cited by 378
Restraining PI3K: mTOR signalling goes back to the membrane
Harrington, L. S., Findlay, G. M., & Lamb, R. F. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.11.003 · Cited by 366
Jou, S.-T., Carpino, N., Takahashi, Y., Piekorz, R., Chao, J.-R., Carpino, N., Wang, D., & Ihle, J. N. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8580-8591.2002 · Cited by 357
High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice.
Stambolic, V., Tsao, M., MacPherson, D. P., Suzuki, A., Chapman, W. B., & Mak, T. W. (2000) · PubMed · Cited by 356
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.-H., Mullholland, D. J., Magnuson, M. A., Wu, H., & Sabatini, D. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.017 · Cited by 355
Guillermet-Guibert, J., Bjorklof, K., Salpekar, A., Gonella, C., Ramadani, F., Bilancio, A., Meek, S., Smith, A. J. H., Okkenhaug, K., & Vanhaesebroeck, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707761105 · Cited by 345
Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q., & Testa, J. R. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199802)21:2<81::aid-mc1>3.3.co;2-k · Cited by 329
Zhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F., & Roberts, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508988102 · Cited by 324
Self-citationEarly embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase
Bi, L., Okabe, I., Bernard, D. J., & Nussbaum, R. L. (2002) · Mammalian Genome · doi:10.1007/bf02684023 · Cited by 318
Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V. B., Lansing, T. J., McConnell, R. T., Gilmer, T. M., Zhang, S.-Y., Robell, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5783 · Cited by 295
Fruman, D. A., Mauvais-Jarvis, F., Pollard, D. A., Yballe, C. M., Brazil, D., Bronson, R. T., Kahn, C. R., & Cantley, L. C. (2000) · Nature Genetics · doi:10.1038/81715 · Cited by 293
The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis
Hamada, K., Sasaki, T., Koni, P. A., Natsui, M., Kishimoto, H., Sasaki, J., Yajima, N., Horie, Y., Hasegawa, G., Naito, M., et al. (2005) · Genes & Development · doi:10.1101/gad.1308805 · Cited by 287
Phosphoinositide 3-Kinase γ Is an Essential Amplifier of Mast Cell Function
Laffargue, M., Calvez, R., Finan, P., Trifilieff, A., Barbier, M., Altruda, F., Hirsch, E., & Wymann, M. P. (2002) · Immunity · doi:10.1016/s1074-7613(02)00282-0 · Cited by 286
Clinical role of positron emission tomography in oncology
Bomanji, J., Costa, D., & Ell, P. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00257-6 · Cited by 281
Garlich, J. R., De, P., Dey, N., Su, J. D., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G. B., Kundra, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0669 · Cited by 279
Taniguchi, C. M., Kondo, T., Sajan, M., Luo, J., Bronson, R., Asano, T., Farese, R., Cantley, L. C., & Kahn, C. R. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.04.005 · Cited by 279
Solit, D. B., Basso, A. D., Olshen, A. B., Scher, H. I., & Rosen, N. X. (2003) · PubMed · Cited by 277
A novel AKT3 mutation in melanoma tumours and cell lines
Davies, M. A., Stemke-Hale, K., Tellez, C., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J. F., Gershenwald, J. E., & Mills, G. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604637 · Cited by 272
Ciraolo, E., Iezzi, M., Marone, R., Marengo, S., Curcio, C., Costa, C., Azzolino, O., Gonella, C., Rubinetto, C., Wu, H., et al. (2008) · Science Signaling · doi:10.1126/scisignal.1161577 · Cited by 269
A New Mutational aktivation in the PI3K Pathway
Brugge, J., Hung, M.-C., & Mills, G. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.014 · Cited by 263
The deficiency of Akt1 is sufficient to suppress tumor development in Pten +/− mice
Chen, M.-L., Xu, P.-Z., Peng, X., Chen, W. S., Guzman, G., Yang, X., Di Cristofano, A., Pandolfi, P. P., & Hay, N. (2006) · Genes & Development · doi:10.1101/gad.1395006 · Cited by 241
Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase
Ueki, K., Yballe, C. M., Brachmann, S. M., Vicent, D., Watt, J. M., Kahn, C. R., & Cantley, L. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012581799 · Cited by 234
Analysis of PTEN and the 10q23 region in primary prostate carcinomas
Feilotter, H. E., Nagai, M. A., Boag, A. H., Eng, C., & Mulligan, L. M. (1998) · Oncogene · doi:10.1038/sj.onc.1200205 · Cited by 230
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
Wu, G., Xing, M., Mambo, E., Huang, X., Liu, J., Guo, Z., Chatterjee, A., Goldenberg, D., Gollin, S. M., Sukumar, S., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1262 · Cited by 228
Human cancer, PTEN and the PI-3 kinase pathway
Parsons, R. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2003.12.021 · Cited by 224
Zhao, J. J., Cheng, H., Jia, S., Wang, L., Gjoerup, O. V., Mikami, A., & Roberts, T. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607899103 · Cited by 224
Self-citationMassion, P. P., Kuo, W.-L., Stokoe, D., Olshen, A. B., TRESELER, P. A., Chin, K., Chen, C., Polikoff, D., Jain, A. N., Pinkel, D., et al. (2002) · PubMed · Cited by 222
Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.
Wang, S. I., Parsons, R. E., & Ittmann, M. (1998) · PubMed · Cited by 218
AKT1E17K in human solid tumours
Bleeker, F. E., Felicioni, L., Buttitta, F., Lamba, S., Cardone, L., Rodolfo, M., Scarpa, A., Leenstra, S., Frattini, M., Barbareschi, M., et al. (2008) · Oncogene · doi:10.1038/onc.2008.170 · Cited by 209
Puri, K. D., Doggett, T. A., Douangpanya, J., Hou, Y., Tino, W. T., Wilson, T., Graf, T., Clayton, E., Turner, M., Hayflick, J. S., et al. (2004) · Blood · doi:10.1182/blood-2003-05-1667 · Cited by 200
Involvement of Hsp90 in Signaling and Stability of 3-Phosphoinositide-dependent Kinase-1
Fujita, N., Sato, S., Ishida, A., & Tsuruo, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106736200 · Cited by 198
Boström, J. P., Cobbers, J. M. J. L., Wolter, M., Tabatabai, G., Weber, R. G., Lichter, P., Collins, V. P., & Reifenberger, G. (1998) · PubMed · Cited by 194
Uncommon Mutation, but Common Amplifications, of the PIK3CA Gene in Thyroid Tumors
Wu, G., Mambo, E., Guo, Z., Hu, S., Huang, X., Gollin, S. M., Trink, B., Ladenson, P. W., Sidransky, D., & Xing, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2281 · Cited by 191
Malanga, D., Scrima, M., De Marco, C., Fabiani, F., De Rosa, N., de Gisi, S., Malara, N., Savino, R., Rocco, G., Chiappetta, G., et al. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5485 · Cited by 190
Oda, K., Okada, J., Timmerman, L., Rodriguez-Viciana, P., Stokoe, D., Shoji, K., Taketani, Y., Kuramoto, H., Knight, Z. A., Shokat, K. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0755 · Cited by 189
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms
Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y., Velculescu, V. E., Wang, T.-L., & Shih, I.-M. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2751 · Cited by 187
Byun, D., Cho, K., Ryu, B., Lee, M., Park, J., Chae, K., Kim, H., & Chi, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.10962 · Cited by 184
Brachmann, S. M., Ueki, K., Engelman, J. A., Kahn, R. C., & Cantley, L. C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1596-1607.2005 · Cited by 179
Schnell, C. R., Stauffer, F., Allegrini, P. R., O'Reilly, T., McSheehy, P. M. J., Dartois, C., Stumm, M., Cozens, R., Littlewood-Evans, A., García-Echeverría, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1044 · Cited by 174
Hsp90: A Novel Target for Cancer Therapy
Solit, D., & Rosen, N. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812068 · Cited by 170
p84, a New Gβγ-Activated Regulatory Subunit of the Type IB Phosphoinositide 3-Kinase p110γ
Suire, S., Coadwell, J., Ferguson, G. J., Davidson, K., Hawkins, P., & Stephens, L. (2005) · Current Biology · doi:10.1016/j.cub.2005.02.020 · Cited by 164
Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
Kim, M. S., Jeong, E. G., Yoo, N. J., & Lee, S. H. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604212 · Cited by 163
Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN
Gray, I., Stewart, L., Phillips, S. M. A., Hamilton, J., Gray, N. E., Watson, G., Spurr, N., & Snary, D. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.674 · Cited by 154
Ihle, N. T., Paine-Murrieta, G. D., Berggren, M. I., Baker, A. F., Tate, W. R., Wipf, P., Abraham, R. T., Kirkpatrick, D. L., & Powis, G. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0149 · Cited by 154
Woenckhaus, J., Steger, K., Werner, E., Fenic, I., Gamerdinger, U., Dreyer, T., & Stahl, U. (2002) · The Journal of Pathology · doi:10.1002/path.1207 · Cited by 152
Webb, L. M. C., Vigorito, E., Wymann, M. P., Hirsch, E., & Turner, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.2783 · Cited by 148
Hypomorphic Mutation of PDK1 Suppresses Tumorigenesis in PTEN+/− Mice
Bayascas, J. R., Leslie, N. R., Parsons, R. E., Fleming, S., & Alessi, D. R. (2005) · Current Biology · doi:10.1016/j.cub.2005.08.066 · Cited by 147
D-21266, a New Heterocyclic Alkylphospholipid with Antitumour Activity
Hilgard, P., Klenner, T., Stekar, J., Nössner, G., Kutscher, B., & Engel, J. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00466-2 · Cited by 144
PIK3CA mutation and amplification in human lung cancer
Okudela, K., Suzuki, M., Kageyama, S., Bunai, T., Nagura, K., Igarashi, H., Takamochi, K., Suzuki, K. Z., Yamada, T., Niwa, H., et al. (2007) · Pathology International · doi:10.1111/j.1440-1827.2007.02155.x · Cited by 142
Mutation and Allelic Loss of the PTEN/MMAC1 gene in Primary and Metastatic Melanoma Biopsies
Birck, A., Ahrenkiel, V., Zeuthen, J., HOU-JENSEN, K., & Guldberg, P. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00877.x · Cited by 141
Early Involvement of the Phosphatidylinositol 3-Kinase/Akt Pathway in Lung Cancer Progression
Massion, P. P., Taflan, P. M., Shyr, Y., Rahman, S. M. J., Yildiz, P., Shakthour, B., Edgerton, M. E., Ninan, M., Andersen, J. J., & Gonzalez, A. L. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-487oc · Cited by 141
Amplicon profiles in ovarian serous carcinomas
Nakayama, K., Nakayama, N., Jinawath, N., Salani, R., Kurman, R. J., Shih, I., & Wang, T. (2007) · International Journal of Cancer · doi:10.1002/ijc.22609 · Cited by 141
Torbett, N., Luna-Moran, A., Knight, Z. A., Houk, A., Moasser, M., Weiss, W., Shokat, K., & Stokoe, D. (2008) · Biochemical Journal · doi:10.1042/bj20080639 · Cited by 138
Genetic Alterations of Phosphoinositide 3‐kinase Subunit Genes in Human Glioblastomas
Mizoguchi, M., Nutt, C. L., Mohapatra, G., & Louis, D. N. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00080.x · Cited by 136
Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.
Miller, C. T., Moy, J. R., Lin, L., Schipper, M. J., Normolle, D. P., Brenner, D. E., Iannettoni, M. D., Orringer, M. B., & Beer, D. G. (2003) · PubMed · Cited by 135
Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma
Feilotter, H. E., Coulon, V., McVeigh, J. L., Boag, A. H., Dorion-Bonnet, F., Duboué, B., Latham, W. C. W., Eng, C., Mulligan, L. M., & Longy, M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690115 · Cited by 133
PTEN/MMAC1/TEP1 involvement in primary prostate cancers
Pesche, S., Latil, A., Muzeau, F., Cussenot, O., Fournier, G., Longy, M., Eng, C., & Lidereau, R. (1998) · Oncogene · doi:10.1038/sj.onc.1202081 · Cited by 131
Bénistant, C., Chapuis, H., & Roche, S. (2000) · Oncogene · doi:10.1038/sj.onc.1203871 · Cited by 129
Voigt, P., Dorner, M. B., & Schaefer, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512502200 · Cited by 127
Chemically targeting the PI3K family
Knight, Z. A., & Shokat, K. M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350245 · Cited by 125
Luo, J., Sobkiw, C. L., Hirshman, M. F., Logsdon, M. N., Li, T. Q., Goodyear, L. J., & Cantley, L. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.04.003 · Cited by 124
Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype
Garcia, J. M., Silva, J. M., Domínguez, G., Gonzalez, R. M., Navarro, A., Carretero, L., Provencio, M., España, P., & Bonilla, F. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006273516976 · Cited by 122
Knobbe-Thomsen, C. B., Lapin, V., Suzuki, A., & Mak, T. W. (2008) · Oncogene · doi:10.1038/onc.2008.238 · Cited by 113
Essential role of PI3Kδ and PI3Kγ in thymocyte survival
Swat, W., Montgrain, V., Doggett, T. A., Douangpanya, J., Puri, K. D., Vermi, W., & Diacovo, T. G. (2005) · Blood · doi:10.1182/blood-2005-08-3300 · Cited by 111
Tassi, I., Cella, M., Gilfillan, S., Turnbull, I. R., Diacovo, T. G., Penninger, J. M., & Colonna, M. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.014 · Cited by 107
Guo, H., Samarakoon, A., Vanhaesebroeck, B., & Malarkannan, S. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072327 · Cited by 105
Deletion of the phosphoinositide 3-kinase p110γ gene attenuates murine atherosclerosis
Chang, J. D., Sukhova, G. K., Libby, P., Shvartz, E., Lichtenstein, A. H., Field, S. J., Kennedy, C. E., Madhavarapu, S., Luo, J., Wu, D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702663104 · Cited by 104
p50α/p55α Phosphoinositide 3-Kinase Knockout Mice Exhibit Enhanced Insulin Sensitivity
Chen, D., Mauvais‐Jarvis, F., Blüher, M., Fisher, S. J., Jozsi, A. C., Goodyear, L. J., Ueki, K., & Kahn, C. R. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.24.1.320-329.2004 · Cited by 101
PIK3CA alterations in primary (de novo) and secondary glioblastomas
Kita, D., Yonekawa, Y., Weller, M., & Ohgaki, H. (2007) · Acta Neuropathologica · doi:10.1007/s00401-006-0186-1 · Cited by 100
Class 1A PI3K regulates vessel integrity during development and tumorigenesis
Yuan, T. L., Choi, H. S., Matsui, A., Benes, C. H., Lifshits, E., Luo, J., Frangioni, J. V., & Cantley, L. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804123105 · Cited by 99
Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α
Zunder, E. R., Knight, Z. A., Houseman, B. T., Apsel, B., & Shokat, K. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.014 · Cited by 96
Kim, N., Saudemont, A., Webb, L. M. C., Camps, M., Rückle, T., Hirsch, E., Turner, M., & Colucci, F. (2007) · Blood · doi:10.1182/blood-2007-02-075366 · Cited by 95
Yu, K., Toral‐Barza, L., Shi, C., Zhang, W., & Zask, A. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.2.5334 · Cited by 92
Identification of PTEN mutations in metastatic melanoma specimens
Çelebi, J. T., Shendrik, I., Silvers, D. N., & Peacocke, M. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.9.653 · Cited by 90
PIK3CA gene amplification in Japanese non-small cell lung cancer
Kawano, O., Sasaki, H., Okuda, K., Yukiue, H., Yokoyama, T., Yano, M., & Fujii, Y. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.06.020 · Cited by 89
Phosphatidylinositol 3-Kinase Regulates the CD4/CD8 T Cell Differentiation Ratio
Rodríguez-Borlado, L., Barber, D. F., Hernández, C., Marcos, M. A. R., Sánchez, A., Hirsch, E., Wymann, M. P., Martínez‐A, C., & Carrera, A. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.9.4475 · Cited by 79
REIFENBERGER, J., Wolter, M., Bostr�m, J., B�schges, R., Megahed, M., Ruzicka, T., Schulte, K. W., & Reifenberger, G. (2000) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280050477 · Cited by 79
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma
Fenic, I., Steger, K., Gruber, C., Arens, C., & Woenckhaus, J. (2007) · Oncology Reports · doi:10.3892/or.18.1.253 · Cited by 79
Insights into the oncogenic effects of /PIK3CA/ mutations from the structure of p110α/p85α
Huang, C., Mandelker, D. L., Gabelli, S. B., & Amzel, L. M. (2008) · Cell Cycle · doi:10.4161/cc.7.9.5817 · Cited by 76
Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas
Freihoff, D., Kempe, A. C., Beste, B., Wappenschmidt, B., Kreyer, E., Hayashi, Y., Meindl, A., Krebs, D., Wiestler, O. D., von Deimling, A., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690121 · Cited by 74
PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines
Pollock, P. M., Walker, G. J., Glendening, J. M., Noy, T. Q., Bloch, N. C., Fountain, J. W., & Hayward, N. K. (2002) · Melanoma Research · doi:10.1097/00008390-200212000-00006 · Cited by 74
Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Lindsley, C. W., Stanley, B., Melissa, Y., et al. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607781696864 · Cited by 72
Beeton, C. A., Chance, E. M., Foukas, L. C., & Shepherd, P. R. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3500353 · Cited by 64
Tangled Webs: Evidence of Cross-Talk Between c-Raf-1 and Akt
Jun, T., Gjoerup, O. V., & Roberts, T. M. (1999) · Science Signaling · doi:10.1126/stke.1999.13.pe1 · Cited by 60
Self-citationMiyake, T. M., Yoshino, K., Enomoto, T., Takata, T., Ugaki, H., Kim, A., Fujiwara, K., Miyatake, T., Fujita, M., & Kimura, T. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.11.004 · Cited by 59
In Vivo Molecular Pharmacology and Antitumor Activity of the Targeted Akt Inhibitor PX-316
Meuillet, E. J., Ihle, N. T., Baker, A. F., Gard, J. M. C., Stamper, C., Williams, R. R., Coon, A., Mahadevan, D., George, B. L., Kirkpatrick, L., et al. (2004) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/0965040042380487 · Cited by 53
MacDonald, P. E., Joseph, J. W., Yau, D., Diao, J., Asghar, Z., Dai, F. F., Oudit, G. Y., Patel, M. M., Backx, P. H., & Wheeler, M. B. (2004) · Endocrinology · doi:10.1210/en.2004-0028 · Cited by 48
Gills, J. J., Holbeck, S. L., Hollingshead, M. G., Hewitt, S. M., Kozikowski, A. P., & Dennis, P. A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0484 · Cited by 48
PI3 Kinases in Cancer: From Oncogene Artifact to Leading Cancer Target
Zhao, J. J., & Roberts, T. (2006) · Science's STKE · doi:10.1126/stke.3652006pe52 · Cited by 47
Self-citationLee, J. Y., Engelman, J. A., & Cantley, L. C. (2007) · Science · doi:10.1126/science.1146073 · Cited by 46
Gills, J. J., & Dennis, P. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.7.787 · Cited by 46
Tokunaga, E., Oki, E., Kimura, Y., Yamanaka, T., Egashira, A., Nishida, K., Koga, T., Morita, M., Kakeji, Y., & Maehara, Y. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9295-8 · Cited by 41
Therapeutic Monitoring of Rapamycin
Yatscoff, R. W., LeGatt, D. F., & Kneteman, N. M. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199312000-00004 · Cited by 31
Utermark, T., Schaffhausen, B., Roberts, T. M., & Zhao, J. J. (2007) · Journal of Virology · doi:10.1128/jvi.00115-07 · Cited by 30
Self-citation
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Signaling mechanisms of the epithelial-mesenchymal transition
Gonzalez, D. M., & Medici, D. (2014) · Science Signaling · doi:10.1126/scisignal.2005189 · Cited by 1,721
Jiao, Y., Shi, C., Edil, B. H., de Wilde, R. F., Klimstra, D. S., Maitra, A., Schulick, R. D., Tang, L. H., Wolfgang, C. L., Choti, M. A., et al. (2011) · Science · doi:10.1126/science.1200609 · Cited by 1,717
Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation
Balla, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00028.2012 · Cited by 1,638
Metadata
- Authors
- Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-08
- Volume
- 8
- Issue
- 8
- Pages
- 627-644
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1981711832
- Cited by
- 2,721
- References
- 201
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.